Evidence check: ApoB in the context of menopause

ApoB (apolipoprotein B) is the primary structural protein of atherogenic lipoproteins (LDL, VLDL, IDL) and is considered a more accurate marker of cardiovascular risk than LDL cholesterol alone. During menopause, cardiovascular risk rises sharply due to estrogen decline – estrogen enhances LDL clearance and inhibits lipid oxidation. Studies indicate that postmenopausal women have higher ApoB levels compared to premenopausal women, independent of total cholesterol. Menopause also shifts LDL toward smaller, denser particles, which are more atherogenic and better captured by ApoB. However, the evidence base is not fully robust: no large randomized trials have specifically tested ApoB-lowering interventions in menopause. Most data come from observational studies and post-hoc analyses. Clinical guidelines (e.g., ESC/EAS) recommend ApoB as a secondary target, especially in women with metabolic syndrome or diabetes. In practice, measuring ApoB in menopausal women with elevated risk (e.g., early menopause, family history) can refine treatment decisions. Caveat: ApoB alone does not replace a full lipid panel (LDL, HDL, triglycerides) and should be interpreted alongside lifestyle, inflammatory markers (hsCRP), and hormonal status. Evidence is moderate – mechanistically sound but not confirmed by menopause-specific intervention trials.